Catherine Farinet, MD
Internal Medicine · Piketon, OHNPI 1801821723
Payments from drug & device makers
Across 119 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$501
- Novo Nordisk$282
- Lilly USA, LLC$124
- AstraZeneca$109
- Merck$88
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
- plus $846 from 30 others
What the payments were for
- Food & beverage$1,98398%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $501 |
| Novo Nordisk | 16 | $282 |
| Lilly USA, LLC | 6 | $124 |
| AstraZeneca | 7 | $109 |
| Merck | 5 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Abbott | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Viiv Healthcare Company | 3 | $49 |
| GSK | 3 | $44 |
| Pfizer | 3 | $42 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Exact Sciences | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Novartis | 2 | $32 |
| Grifols USA, LLC | 1 | $29 |
| Intuitive Surgical | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Amgen | 1 | $19 |
| Cipher Pharmaceuticals US LLC | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Indivior Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 2 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Theratechnologies Inc. | 1 | $12 |
How this compares
$2,028 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 207 | $244,594 |
| MounjaroTirzepatide | 132 | $160,138 |
| EliquisApixaban | 452 | $159,131 |
| AustedoDeutetrabenazine | 13 | $143,848 |
| XifaxanRifaximin | 72 | $126,236 |
| VraylarCariprazine Hcl | 147 | $85,133 |
| Invega SustennaPaliperidone Palmitate | 27 | $79,902 |
| OzempicSemaglutide | 50 | $63,834 |
| LinzessLinaclotide | 72 | $47,253 |
| XareltoRivaroxaban | 57 | $45,650 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $39,172 |
| JanuviaSitagliptin Phosphate | 44 | $35,399 |
| FarxigaDapagliflozin Propanediol | 49 | $34,551 |
| AptiomEslicarbazepine Acetate | 53 | $33,992 |
| PerserisRisperidone | 14 | $33,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $124 | $404,732339 claims |
| PfizerEliquis | $42 | $159,131452 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $35 | $143,84813 claims |
| AbbVieVraylar, Linzess | $501 | $132,386219 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $78 | $126,23672 claims |
| Novo NordiskOzempic, Rybelsus | $282 | $95,20271 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $44 | $67,730110 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $109 | $58,24680 claims |
| MerckJanuvia | $88 | $35,39944 claims |
| Indivior Inc.Perseris | $16 | $33,09014 claims |
| Boehringer IngelheimJardiance | $16 | $30,92135 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19 | $20,42312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Piketon
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.